menu
    • menu

    Company profile for Aboleris Pharma

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Aboleris Pharma is a dynamic pharmaceutical company committed to developing and commercializing innovative therapies that address unmet medical needs. With a focus on research-driven solutions, we strive to improve patient outcomes through cutting-edge science and strategic partnerships. Our expertise spans drug development, manufacturing, and global distribution, ensuring high-quality, accessible treatments.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aboleris PharmaBelgium Flag
    Country
    Country
    Belgium
    Address
    Address
    Rue Antoine de Saint Exupéry 14 6041 Gosselies
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://aboleris-pharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aboleris Pharma Initiates Phase 1 Study Part II for ABO-21009
    Aboleris Pharma Initiates Phase 1 Study Part II for ABO-21009

    08 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aboleris-pharma-announces-first-patient-dosed-in-part-ii-of-phase-1-study-of-abo21009-a-novel-anti-cd45rc-antibody-for-rheumatoid-arthritis-302655891.html

    PR NEWSWIRE
    08 Jan 2026
    Share Share
    Aboleris Pharma Reveals New Preclinical Data On ABO21009
    Aboleris Pharma Reveals New Preclinical Data On ABO21009

    12 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aboleris-pharma-announces-publication-in-molecular-therapy-cell-press-journal-of-new-preclinical-results-supporting-mechanism-of-action-of-abo21009-a-first-in-class-anti-cd45rc-antibody-currently-in-phase-1-302612332.html

    PR NEWSWIRE
    12 Nov 2025
    Share Share
    Aboleris Pharma Appoints Philippe Alen as Chief Business Officer
    Aboleris Pharma Appoints Philippe Alen as Chief Business Officer

    30 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aboleris-pharma-appoints-seasoned-life-sciences-executive-philippe-alen-as-chief-business-officer-302598817.html

    PR NEWSWIRE
    30 Oct 2025
    Share Share
    AbolerIS Doses 1st ABO21009 Patient in RA Ph1 Antibody Study
    AbolerIS Doses 1st ABO21009 Patient in RA Ph1 Antibody Study

    07 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aboleris-pharma-announces-first-cohort-dosed-in-phase-1-study-of-abo21009-a-novel-anti-cd45rc-antibody-for-rheumatoid-arthritis-302447848.html

    PR NEWSWIRE
    07 May 2025
    Share Share
    AbolerIS Pharma Announces Formation of Scientific Advisory Board
    AbolerIS Pharma Announces Formation of Scientific Advisory Board

    24 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aboleris-pharma-announces-formation-of-scientific-advisory-board-302436451.html

    PR NEWSWIRE
    24 Apr 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search